Sök artiklar i SveMed+

Tidskrift

Sammanfattning

BACKGROUND Allogeneic stem cell transplantation (ASCT) has been a treatment option for patients with serious diseases of the blood and haematopoietic organs in Norway since 1985. Such treatment is potentially curative for selected patients who have a relatively short predicted survival with other treatment modalities. This article summarises the experience and results from ASCT at Oslo University Hospital Rikshospitalet. MATERIAL AND METHOD The study included all of the 734 adult patients who had undergone allogeneic stem cell transplantation at the Department of Haematology, Rikshospitalet, later Oslo University Hospital Rikshospitalet, from November 1985 to October 2012. RESULTS At the time of analysis, altogether 384 patients were alive, and the five and ten-year survival rates were 54 % and 48 % respectively. The median follow-up time was six years. A total of 339 patients (46 %) had developed acute graft-versus-host disease (GvHD), and 250 (73 %) of these had GvHD ? grade II. Altogether 280 out of 602 patients who lived ? 100 days after the transplantation (46.5 %) developed chronic GvHD. The most frequent causes of death included recurrence of the initial disease in 116 patients (33.1 %), multi organ failure after transplantation in 88 patients (25.4 %), infections in 54 patients (16 %) and GvHD in 33 patients (9.4 %). INTERPRETATION ASCT is a treatment option with a curative potential for patients with serious haematological diseases when other forms of treatment provide few prospects for recovery. The total survival rate in our study is in accordance with international results for the same time period, and the indications have consistently been in line with what is accepted internationally.

MeSH